Status:
WITHDRAWN
Effect Of Rifampin On Pharmacokinetics Of Sitaxsentan
Lead Sponsor:
Pfizer
Conditions:
Pulmonary Arterial Hypertension
Eligibility:
All Genders
21-55 years
Phase:
PHASE1
Brief Summary
This study will assess how rifampin will affect the blood levels of sitaxsentan. Safety of sitaxsentan given alone and with rifampin will also be assessed.
Eligibility Criteria
Inclusion
- Healthy male subjects and/or women of non-child bearing potential.
- Subjects between the ages of 21 and 55 years, inclusive.
- Signed informed consent.
Exclusion
- Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease.
- Has hepatic dysfunction.
- Has history of excessive alcohol and tobacco use.
Key Trial Info
Start Date :
December 1 2010
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 1 2011
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT01251835
Start Date
December 1 2010
End Date
January 1 2011
Last Update
March 5 2015
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.